Retatrutide interest is moving faster than the regulatory calendar.
In search data, independent testing archives and PeptidePrices internal analytics, retatrutide has climbed from an emerging obesity compound to the dominant subject in several research-market signals. That happened before Lilly completed the Phase 3 clinical package for its initial proposed uses and before the company filed its planned U.S. application.
Is retatrutide FDA approved? Not yet. As of August 24, 2026, Lilly says it plans to submit a Biologics License Application in the first quarter of 2027. The more immediate story is how much interest has already accumulated ahead of that filing.
For the trial results and study citations, see the PeptidePrices retatrutide research profile.
Retatrutide interest moved first
Four external series show the same broad direction over time, and PeptidePrices internal analytics add a current attention snapshot. They are not one combined market-share estimate, but each documents retatrutide's position in a different corner of the market.
| Signal | Earlier period | Recent comparable period | Change |
|---|---|---|---|
| Google Trends, fixed U.S. five-term panel | Five-year mean: 8.1 | Recent 26-week mean: 47.7 | 5.9 times the long-run mean |
| Finnrick, fixed six-compound testing series | H1 2025 retatrutide share: 22.5% | H1 2026 share: 55.4% | Up 32.9 percentage points |
| Freedom Diagnostics, Jan. 1 to Aug. 19 matched windows | 2025 retatrutide share: 11.2% | 2026 share: 16.0% | Up 4.8 percentage points |
| Janoshik, 30 rows displayed in its March 2026 presentation | 2023 retatrutide share: 4.9% | 2025 share: 16.3% | Up 11.4 percentage points |
Figure 1. Each panel uses its own labeled unit, time window and scale. The series are displayed together for comparison, not combined into a single score. Open the chart for the full-size view.
The agreement is directional rather than mathematical. Google Trends captures relative search interest. Finnrick and Freedom track published testing records. Janoshik calls its metric occurrences. The series should be read next to one another, not averaged together.
PeptidePrices internal analytics
From April 15 through August 19, 2026, retatrutide accounted for 40.0% of eligible peptide-detail pageviews in PeptidePrices internal analytics.
That is a current attention snapshot because the analytics property began on April 15. It is presented as a percentage only and is not used as a sales estimate.
Google search interest accelerated in 2026
In a fixed U.S. Google Trends panel comparing Retatrutide, Tirzepatide, BPC-157, MOTS-C and GHK-Cu, retatrutide's five-year mean index was 8.1. Its trailing 52-week mean rose to 34.6, and its most recent 26-week mean reached 47.7.
The shorter the recent window, the higher the average. That is the shape of an accelerating search curve rather than a one-week news spike. The live Google Trends comparison keeps the geography, terms and Web Search setting fixed.
Finnrick shows the testing mix changing over time
Finnrick's monthly series provides the over-time view that a one-date archive total misses. Within a fixed panel of six compounds, retatrutide's share of published records grouped by laboratory test month changed as follows:
| Test period | Retatrutide share of the six-compound Finnrick series |
|---|---|
| First half of 2025 | 22.5% |
| Second half of 2025 | 48.1% |
| First half of 2026 | 55.4% |
This is the current Finnrick database organized by test month. Finnrick can publish qualifying older records later and can revise existing records, so the figures are best read as a dated reconstruction of testing activity, not as frozen historical snapshots.
Freedom Diagnostics and Janoshik point the same way
Freedom Diagnostics gives an apples-to-apples annual comparison. In the January 1 to August 19 window, retatrutide rose from 11.2% of public reports in 2025 to 16.0% in 2026. Using the share avoids confusing the archive's overall expansion with retatrutide-specific growth.
Janoshik's March 2026 presentation shows retatrutide at 4.9% of its 30 displayed rows in 2023 and 16.3% in 2025. Janoshik labels the figures occurrences, so the safest reading is a rising share within that presentation rather than a customer or purchase count.
The regulatory timeline is now coming into focus
The attention curve developed first. Lilly's formal timeline is now beginning to catch up.
| Date | Retatrutide milestone |
|---|---|
| July 23, 2026 | Lilly reported positive topline results from TRIUMPH-2 and TRIUMPH-3. It said detailed data would follow at medical meetings and in peer-reviewed publications while it completed the Chemistry, Manufacturing and Controls package. |
| August 5, 2026 | Lilly said three additional Phase 3 trials were positive and the clinical package was complete for obesity, obstructive sleep apnea and knee osteoarthritis pain. |
| August 13, 2026 | Lilly Canada issued a public-safety notice confirming retatrutide had not been approved for human use by Health Canada or any other regulator. |
| Q1 2027, planned | Lilly expects to submit a U.S. Biologics License Application. |
| After submission | FDA must decide whether to accept the application for review, evaluate the clinical and manufacturing package, work through labeling and issue a decision. No approval date has been announced. |
Lilly's August 5 quarterly update established the clinical-package milestone and the planned Q1 2027 submission. Its July 23 Phase 3 release provides the trial and manufacturing context.
The planned BLA also connects to the unresolved question of why retatrutide is being discussed as a biologic rather than through the conventional new-drug pathway. Our retatrutide drug-or-biologic classification explainer covers the amino-acid threshold, Lilly's position, the FDA dispute and what the classification could mean for competition and future access.
What Phase 3 completion changes
Completing the clinical package gives Lilly the efficacy and safety evidence it expects to use in the application. It also means the near-term milestones shift from trial readouts toward complete publication, submission, FDA filing and regulatory review.
Important details remain open. Full results from every recent Phase 3 trial have not yet appeared in peer-reviewed publications. FDA has not reviewed the complete application, and the eventual indication, dose schedule, warnings and label language will depend on that process.
This is why Q1 2027 is the next concrete date to watch. It is a planned submission window, not a launch date.
What public COAs show in the current market
Interest in retatrutide is already visible in the volume of public testing and vendor documentation. The links below go directly to each retatrutide listing and public COA library. Where PeptidePrices retained or verified a specific report, the report details are included.
| Vendor and direct links | Reviewed retatrutide documentation | Lot linkage | Panel observed |
|---|---|---|---|
| Chameleon Peptides: current COA ledger · archived Batch B002 report | The live ledger now lists Batch B003 GLP-3 documentation and retains earlier Batch B002 reports | Current Batch B003 plus archived B002 | Current B003 entries cover identity, measured amount, HPLC purity, endotoxin, heavy metals and sterility where listed |
| Puratek Peptides: PUR-3R listing · certification library | ILS Laboratories Retatrutide 30mg report analyzed July 7, 2026: 99.23% purity and 30.81mg measured content | Named product lot with QR-linked ILS verification code | Identity, purity, content, fentanyl screen, heavy metals, sterility and endotoxin |
| Amino Club: GLP-3 listing · COA directory · ILS verification record | ILS Full QC Panel for GLP-3 RT 10mg, issued May 29, 2026: 99.85% reported purity and 10.27mg measured content | Lot RT0001, COA-2026-23VVJS | Identity, purity, two-vial conformity, content, ICP-MS heavy metals, PCR sterility and USP 85 endotoxin |
| Glacier Aminos: GLA-3 RT listing · COA directory · Kovera verification portal | Sampled Kovera report KVR-2026-0D8A68 for GLP3-R 10mg: 99.956% batch-average purity and 11.39mg average content | Batch RET10GA-03, access code LAYC3L9 | LC-MS identity, RP-HPLC purity, three-vial conformity, content, endotoxin, microbial sterility and heavy metals |
| Mile High Compounds: MHC-3 RT listing · COA library | The public library lists MHC-3 RT in 5mg, 10mg, 20mg, 30mg and 50mg strengths with current and previous-batch report links | Batch identifiers are shown beside the relevant report links | Panel scope varies by linked record; the library includes Kovera, Chromate, ILS, Google Drive and same-domain report assets, so the exact lot and issuing lab should be checked |
A COA can document identity, purity, measured content and any additional panel results for the submitted sample. The most useful reports also provide a product strength, lot identifier and laboratory verification route. The PeptidePrices COA checker and verification guide explains how to read those fields.
No seller paid for, commissioned or approved this analysis. PeptidePrices participates in affiliate programs with some businesses in its broader directory, but affiliate status did not control inclusion or the evidence standard.
The two retatrutide clocks are converging
Retatrutide now has two timelines.
The first is the interest curve. Search attention accelerated, retatrutide took a larger share of independent testing archives, and it became the leading peptide-detail topic in PeptidePrices internal analytics.
The second is the regulatory calendar. Lilly completed its initial Phase 3 clinical package in 2026 and plans to submit in Q1 2027. FDA review comes after that filing.
Those clocks are finally moving toward the same point. The market is already paying attention. The next formal checkpoint is Lilly's application.
Retatrutide FDA approval FAQ
Is retatrutide FDA approved in 2026?
No. As of August 24, 2026, retatrutide is not FDA approved. Lilly says its Phase 3 clinical package is complete and it plans to submit a Biologics License Application in the first quarter of 2027.
What is the current retatrutide FDA timeline?
Lilly completed the Phase 3 clinical package in 2026 and plans a U.S. submission in Q1 2027. FDA must then decide whether to accept the application for review before evaluating the evidence, manufacturing and proposed label. No approval date has been announced.
Why is Lilly planning a Biologics License Application for retatrutide?
Retatrutide sits at the center of a drug-versus-biologic classification dispute. That classification affects the application pathway, competition and possible future compounding. The retatrutide drug-or-biologic classification explainer covers the dispute in detail.
How quickly has retatrutide interest grown?
Retatrutide's recent U.S. Google Trends average is nearly six times its five-year average. Its share of a fixed six-compound Finnrick testing series rose from 22.5% in the first half of 2025 to 55.4% in the first half of 2026, while Freedom Diagnostics and Janoshik also show a rising retatrutide share over comparable periods.
Research and regulatory information only. Not medical advice or legal advice. All analytics and testing figures are dated snapshots.